Liquid biopsy is gradually being applied in the clinical diagnosis and treatment of lung cancer.At pres-ent,with the development of metabolomics,more and more metabolic biomarkers are considered as potential sensitive mark-ers reflecting the occurrence and development of tumors.This article summarizes the changes in the main metabolic pathways of lung cancer,including glucose metabolism,amino acid metabolism,lipid metabolism,sphingolipid metabolism,glycero-phospholipid metabolism,and purine metabolism.Meanwhile,this article reviews the role of metabolic biomarkers in the early diagnosis of lung cancer,predicting disease progression,and evaluating the efficacy of chemotherapy and immunotherapy,aim-ing to provide effective biomarkers for tumor diagnosis and treatment.

Non-small cell lung cancer is one of the primary types of cancer that leads to brain metastases. Approximately 10% of patients with non-small cell lung cancer have brain metastases at the time of diagnosis, and 26%-53% of patients develop brain metastases during the progression of their disease. However, the underlying mechanisms of lung cancer brain metastasis have not been fully elucidated. With the continuous development of single-cell and spatial transcriptomics, the genomic and transcriptomic characteristics of lung cancer brain metastasis are gradually being revealed. In February 2025, the journal Nature Medicine published an article titled "Single-cell and spatial genomic landscape of non-small cell lung cancer brain metastases". This article aims to provide a brief interpretation of the paper for colleagues in research and clinical practice.